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THE WISE INFANT STUDY:  IMPACT OF A MATERNAL PREVENTION OF 
MOTHER-TO-CHILD TRANSMISSION OF HIV (PMTCT) INTERVENTION 
ON INFANT OUTCOMES IN UGANDA 
ANAYS MURILLO 
ABSTRACT 
Background:  The Wise Mama (WM) study was a randomized trial to assess the 
effectiveness of real-time electronic drug monitoring (EDM) on antiretroviral therapy 
(ART) adherence for prevention of mother-to-child transmission of HIV (PMTCT) for 
newly diagnosed, ART-naïve HIV+ pregnant women in Uganda.  Intervention mothers 
received real-time ART reminders via EDM technology and control mothers received 
standard of care.  All infants born to women in the WM study were to receive standard 
PMTCT care: 6 weeks of nevirapine (NVP) ART prophylaxis following birth and HIV 
DNA testing at 6 weeks of life.  Objective:  To test whether infants born to intervention 
mothers would have improved adherence to infant PMTCT guidelines.  Methods:  
Information on delivery, infant NVP prophylaxis, and timing to first infant HIV test were 
abstracted from medical registers.  Descriptive statistics and differences in 1) infant 
prophylaxis administration, and 2) time to infant HIV testing were generated and 
analyzed.  Results:  Of the 121 WM women eligible for WIN, 97 consented and enrolled 
(80%).  There were no differences in receipt of 6-week NVP supply (86.7% of control 
infants, 82.0% of intervention infants, p=0.53).  Infants delivered at non-study health 
facilities were less likely to receive any NVP prophylaxis.  There was no difference in 
mean days to infant’s first HIV test (control 51.9, intervention 51.3, p=0.86).  
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Conclusion:  There were no significant differences in infant adherence to PMTCT 
guidelines between intervention and control groups, though all infants could have had 
improved access to NVP prophylaxis and decreased time to first HIV test. 
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INTRODUCTION 
 
Human Immunodeficiency Virus (HIV)  
HIV is a virus that compromises the human immune system such that the body 
becomes more susceptible to infections and diseases, resulting in acquired 
immunodeficiency syndrome (AIDS) and death.1  Transmission of HIV can occur with 
the exchange of bodily fluids from an HIV-infected (HIV+) individual to an individual 
not infected with HIV, typically via sexual intercourse, during maternal-infant blood 
exchange in utero or at birth, or via breastfeeding.1  Transmission of HIV can be 
prevented, and treatment is available to prevent it from advancing to end-stage disease 
(AIDS), though there is no cure.  Untreated, HIV will progress to AIDS usually within 10 
to 15 years, and ultimately lead to death.1   
The progression of HIV can be categorized into one of three stages:  1) acute HIV 
infection; 2) clinical latency of HIV infection; or 3) AIDS.2  In Stage 1, which lasts 
approximately 6 weeks after infection, the viral load in the body is extremely high and 
the infected individual is very contagious.2  This stage of infection could produce flu-like 
symptoms, although people often do not feel symptomatic, and so are unaware that they 
are HIV+.2  Acute infection can be diagnosed with either a fourth-generation 
antibody/antigen test or a nucleic acid test, given that antibodies are still being generated 
in the setting of acute infection.2  Stage 2 is referred to as asymptomatic HIV infection or 
chronic infection.2  While the immune system decreases viral replication, HIV continues 
with very low reproduction rates.2  Without medication to treat HIV, known as 
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antiretroviral therapy (ART), people can live up to a decade, or longer, in this phase.2  
Though HIV continues to replicate at low levels, HIV infection may still be 
asymptomatic.2  Towards the end of this stage of HIV, viral load begins to increase and 
the number of CD4 (cluster of differentiation 4) T cells, a type of cell important for cell-
mediated immune function and the target for HIV, begins to decrease.2,3  As virus levels 
begin to increase in the body, and people move into Stage 3, people may become 
symptomatic.2  At Stage 3, the most severe phase of HIV infection, HIV has progressed 
to AIDS, characterized by a very high viral load.2  People are diagnosed with AIDS if 
their CD4 cell counts drop below 200 cells/mm or if they develop certain opportunistic 
illnesses such as certain types of pneumonias, cancers, or fungal infections.2  In addition 
to flu-like symptoms, people with AIDS can also experience swollen lymph glands, 
weakness, and weight loss.2  Without ART, patients with AIDS typically survive about 3 
years.2   
People who are HIV+ can infect others at any stage of their HIV infection.  
Depending on the stage of HIV infection, someone who is HIV+ may infect another 
individual unknowingly.  The sooner treatment is initiated after infection, the better the 
immune recovery and protection, with improved prognosis for a near-normal lifespan.  
Treatment can also dramatically reduce the risk of transmitting HIV to someone who is 
uninfected.  Lifelong ART adherence is necessary for effective long-term viral 
suppression.4,5  
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The Impact of HIV  
The HIV epidemic is one of the world’s most serious public health and global 
development challenges.6  In 1981, the first cases of what would later be characterized as 
AIDS were reported, with the first classes of ART drugs developed a remarkably short 
time later, in 1987.  Also in 1987, the World Health Organization (WHO) created its 
Global Programme on Aids, intended to prevent and control AIDS globally.6,7  In 1996, 
the United Nations Programme on HIV and AIDS (UNAIDS) was formed to serve as the 
coordinating body for the United Nations, and to alert the world about AIDS and 
mobilize worldwide efforts to combat it.6  The President’s Plan for Emergency AIDS 
Relief (PEPFAR), authorized in 2003, is a bilateral commitment program by the United 
States Government to support HIV prevention and treatment programs in developing 
countries and is currently the single largest HIV program, with reauthorization through 
2018.8  Significant progress has been made since the 1980s to prevent HIV infection and 
improve the lives of individuals living with HIV and AIDS, yet HIV continues to result in 
morbidity and mortality on a large scale.6 
By the end of 2015, about 36.7 million people were living with HIV and 1.4 
million pregnant women were HIV+, globally.1  The region of the world most affected by 
HIV is Sub-Saharan Africa (Figure 1), and in 2015 there were 25.6 million cases of HIV 
in this region1.  Among these, an estimated 12.2 million were women of child-bearing 
age, of which 5.5% were newly infected with HIV in 2015 (Figure 2 and 3).9  It is 
estimated that PEPFAR supports ART programs, largely in Sub-Saharan Africa, for 
approximately 11.5 million people.10  
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Figure 1.  Map of Sub-Saharan Africa.11  Outlined in red above is Sub-Saharan Africa.  
Denoted by black stars are the countries Djibouti, Somalia, and Sudan, which are 
excluded in the estimation of HIV cases by the UNAIDS.9 
Note: The red star denotes Uganda, the focus of this paper.  
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Figure 2.  Distribution of Prevalent Female HIV Infections in Sub-Saharan Africa in 
2015.  Of the approximate 25.6 million people living with HIV in Sub-Saharan Africa in 
2015, about 14.2 million were females ages 15 and up.     
*Prevalence proportions were generated using estimations of total number of people living with 
HIV reported by UNAIDS.9 
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Figure 3.  Distribution of Incident Female HIV infections in Sub-Saharan Africa in 
2015.  Of the approximate 25.6 million people living with HIV in Sub-Saharan Africa in 
2015, about 14.2 million were females ages 15 and up, and of these females 710,000 
were newly infected with HIV. 
*Incidence proportions were generated using estimations of newly diagnosed cases of HIV 
reported by UNAIDS.9 
 
 
 
Prevention of Mother-to-Child Transmission of HIV (PMTCT) 
 
Vertical transmission is mother-to-child transmission of HIV (MTCT), either in 
utero, or during labor, delivery, or breastfeeding12.  Prevention of mother-to-child 
transmission of HIV (PMTCT) includes the initiation or maintenance of ART for all 
HIV+ pregnant women, in addition to the provision of an ARV medication (typically 
Incident HIV Infections Among Females by Age in 
Sub-Saharan Africa in 2015*
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7 
 
nevirapine, NVP) at delivery, and the provision of NVP prophylaxis for all HIV-exposed 
infants for 6 weeks after birth.  In the absence of PMTCT, transmission rates from mother 
to infant can be as high as 30% to 40%.13  However, with appropriate PMTCT, 
transmission from mother to infant can be reduced to less than 3%.13  In 2012, the WHO 
adopted Option B+, an update to the existing PMTCT antiretroviral program options.14  
Under this programmatic update, the WHO recommended removing CD4 or disease state 
thresholds necessary to initiate ART treatment, and all HIV+ pregnant women receive 
lifelong ART, regardless of CD4 count.  Lifelong ART provides all HIV+ pregnant 
women with immediate treatment if needed and extended protection from vertical 
transmission of HIV to their children.  If women adhere to treatment, protection can span 
their entire life, and extend to future pregnancies.14  
Most PMTCT approaches have focused on pregnant women who are diagnosed 
HIV+ during antenatal care (ANC).15  However, maternal seroconversion after antenatal 
screening also contributes to the pediatric HIV burden.15  When a mother seroconverts 
during late pregnancy or breastfeeding, it becomes increasingly difficult to prevent HIV 
transmission.15  Acutely infected women have high viral loads, which in addition to 
increasing risk of transmission to the fetus or infant, can also impede proper transfer of 
antibodies from mother-to-child, due to a compromised maternal immune system.16  
Women who seroconvert after antenatal screening are more difficult to identify, thus 
missing the opportunity to initiate PMTCT practices, and in a population most at-risk of 
transmitting the virus given high viral loads.15  A recent national observational cohort in 
South Africa found that MTCT occurred among mother-baby dyads in which the mother 
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had tested negative for HIV antenatally with no documented use of ART drugs.17  Among 
the 9802 women in this cohort, in 2.2% of women, which accounted for 26% of early 
MTCT, their infants tested HIV+ at 4 to 8 weeks postpartum from 2011 to 2012, 
suggesting either misdiagnosis at first antenatal screening or, more likely, late 
seroconversion during pregnancy.17  Less than 60% of the women in this study knew 
their infant’s father’s HIV status during pregnancy or breastfeeding, suggesting that 
women who are unaware of the HIV status of their partner may be at risk of 
seroconverting, and consequently miss the opportunity to prevent MTCT.17  Importantly, 
the WHO recommends that PMTCT settings offer all pregnant women couples 
counselling and testing for HIV.14 
 
Uganda and PMTCT 
Uganda is a country in East-Central Africa and one of the 21 priority countries set 
by the Global Plan.18,19  The Global Plan was the UNAIDS strategy launched in 2011 to 
eliminate new HIV infections among children by 2015, and to keep their mothers alive in 
countries with high HIV-burden.19  In 2015, Uganda had an estimated population of 
39,032,383 people and an estimated HIV prevalence of 3.8%.20  Among people ages 15 
to 49 years, the HIV prevalence was higher, at 7.1% in 2015.20  In total, 28,000 adults 
and children died from HIV or AIDS in 2015.20   
In 2013, Uganda adopted the WHO policy Option B+ for PMTCT, which 
mandated lifelong ART for HIV+ pregnant women upon ANC initiation, in a change 
from previous Ugandan PMTCT policy that reserved ART initiation based on the 
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mother’s disease stage of HIV (Option B).21  Option B+ in Uganda also includes 
prophylactic NVP for all exposed infants, including:  1) NVP administration at birth, 2) 
prophylactic NVP for the first 6 weeks of life regardless of feeding modality, and 3) early 
infant diagnosis of HIV (EID) testing at 6 weeks of life.14  Infants testing positive with 
HIV deoxyribonucleic acid (DNA) testing require immediate ART treatment, while 
infants testing negative require a follow up test at 6 months of life, 12 months of life, and 
then once breastfeeding ceases.14  The recommended method of feeding infants for HIV+ 
mothers is at least 6 months of exclusive breastfeeding (EBF).22,23  
In 2014, HIV prevalence in pregnant women was approximately 8.0%.24  By the 
end of 2014 an estimated 5,200 infants were born infected with HIV, compared to an 
estimated 15,000 in 2013, and an estimated 31,000 infants in 2011, thus demonstrating 
increasing PMTCT success in Uganda with the adoption of Option B+.24  However, while 
an estimated 84% of HIV+ pregnant women received ART in 2014 in Uganda, only 25% 
of HIV-exposed infants received ART for PMTCT that year.24  Magnifying this 
discrepancy is the lack of information on infant adherence to NVP prophylaxis and EID 
testing at 6 weeks of life.  PMTCT efficacy relies on both maternal and infant 
continuation and adherence to PMTCT activities, yet the available data on maternal 
retention of care and adherence overwhelmingly exceeds information regarding the infant 
equivalent.25,26  Notably, studies involving PMTCT programs predating Option B+ reveal 
high loss to follow-up (LTFU) for both enrolled mothers and their infants.27–32  Infant 
LTFU rates from PMTCT programs (in Sub-Saharan Africa) pre-Option B+ ranged 
anywhere from 5 to 75% within the first 3 months of delivery.25,26,33–35  As the first 
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country to implement Option B+, Malawi had even higher levels of LTFU following the 
program’s implementation.36  Pregnant women who started ART during pregnancy under 
Option B+ were 5 times more likely to be lost to follow-up after their initial clinic visit 
compared to women enrolled in pre-Option B+ options in the later stages of HIV.36  
These levels of LTFU, even after the advent of Option B+, prevent achievement of 
maximum benefits from PMTCT activities.  
   
Electronic Drug Monitoring (EDM) for Monitoring ART Adherence 
EDM is a definitive measurement of drug adherence in which an embedded 
microprocessor records the date and time of opening or actuation of a drug dispenser.37  It 
provides precise information on how a patient uses medication, such as how often and 
when drug doses are missed.37  Depending on the type of drug, EDM can reveal 
deliberate deviations from medication regimens based on the frequency and duration of 
opening or actuation of a drug dispenser.37  Opening or actuation could also be 
accidental, thus falsely indicating non-adherence.37  Nevertheless, this technology has 
been instrumental in understanding the relationship between ART adherence and HIV-
related clinical outcomes, such as how ART adherence is necessary for long-term viral 
suppression.4,5  Investigators at Boston University’s Center for Global Health and 
Development (BUCGHD) have demonstrated, in two separate interventions in China, 
improved ART adherence with the use of EDM in HIV+ adults.38–40  Other investigators 
pilot tested a wireless pill container (WPC), capable of transmitting a cellular signal when 
opened, in 10 Ugandan individuals over the span of 6 months.41  These investigators 
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found real-time adherence monitoring to be feasible in Uganda, and concluded that this 
type of EDM could detect suboptimal adherence to ART prior to viral rebound in 
resource-limited settings.41 
Though EDM provides precise data on regimen adherence, it is more expensive 
and inconvenient than other methods used to assess adherence to a medication regimen.37  
Some patients have also reported feeling anxious and depressed knowing that their 
behavior is being monitored.37  Despite the financial and logistic barriers to EDM use in 
daily life, EDM technology can serve as a useful tool for studying chronic medication 
adherence, given its accuracy and precision.37,42  EDM appropriately measures actual 
adherence.5,37,42,43 
 
SPECIFIC AIMS 
 
Since the adoption of Option B+ in Uganda and worldwide since 2013, the impact 
measurement of this new policy is crucial.  This paper discusses an ambidirectional 
cohort study, called the Wise Infant (WIN) study, which is a sub-study within the Wise 
Mama (WM) randomized control trial (NIH 1R34MH103075-01A1, BUMC IRB 
Number H-32876).  The WM study is a randomized 2-step feedback intervention to 
assess the effectiveness of real-time EDM on adherence to ART for PMTCT for newly 
HIV diagnosed, ART-naïve pregnant women in Uganda.  Infants of the WIN study are a 
sub-set of the infants in the WM study.  The WIN study examines retention in care of 
HIV-exposed infants born to mothers enrolled in the WM trial, and their adherence to the 
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respective pediatric components of PMTCT activities.  The WIN study hypothesizes that 
the infants born to intervention mothers receiving real-time ART reminders and 
adherence feedback would have improved adherence to the infant components of the 
PMTCT guidelines compared to infants born to control mothers, measured by receipt of 
infant NVP at birth, as well as receipt and time to EID testing at 6 weeks of life.   
Among WIN mother-baby dyads, this paper also explores mothers’ beliefs and 
knowledge about vertical transmission of HIV to their babies and best feeding behaviors 
via questionnaire.  The mothers’ answers to direct questioning at baseline, in conjunction 
with WIN study results, give insight into mothers’ behaviors resulting from study health 
facilities promoting PMTCT practices.  Of note, all pediatric components of PMTCT are 
contingent on mothers or caregivers adhering to feeding modalities, administering ARV 
prophylaxis to infants, and ensuring infants receive EID testing. 
 
METHODS 
 
Study Sites and Subjects 
The WM and WIN studies represent a collaboration between BUCGHD and 
Mildmay Uganda, a national Non-Government Organization established in 1998 in 
Uganda as a Centre of Excellence for the provision of comprehensive HIV and AIDS 
prevention, care, and treatment, as well as training services.44  Institutional review board 
approval for the WIN study was obtained from BUCGHD, Mildmay Uganda, and the 
Uganda National Council of Science and Technology (UNCST). 
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ANC clinics in central Uganda with high volumes of patients were selected for 
the study.  Study sites included 1) ANC clinic at Entebbe Grade B Hospital in Wakiso 
district and 2) ANC clinic at Mityana Hospital in Mityana district (Figure 4).  Both sites 
are public government health facilities where women concurrently receive antenatal and 
ART services.45,46  Pregnant women were eligible for the WM study if they were HIV+, 
18 years of age or older, ART-naïve upon initiating ART at either study health facility, 
and planning to continue to receive care and deliver at the study facilities.  A total of 165 
pregnant women met inclusion criteria and were enrolled in the WM study (Table 1).  
Several characteristics among the women were measured at baseline (Table 2).   
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Figure 4.  Map of Uganda.47  Above in light tan is Uganda.  Denoted by a red square 
and a red triangle is the study site in Entebbe and the study site in Mityana, respectively.  
The capital of Uganda, Kampala, is denoted by a black star. 
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Table 1:  Inclusion and Exclusion Criteria for WM Study48 
Inclusion Criteria • HIV+ pregnant women 
o Between 18 and 59 years of age 
o Receive ANC and are ART-naïve upon initiating 
ART at a study health facility 
o Between 18 and 26 weeks of estimated gestation 
o Able to use a cell phone that can receive text 
messages 
o Provide written informed consent 
Exclusion Criteria • Women with any previous ARV medication experience 
• Women unable to receive text messages in their 
respective homes 
• Women unwilling to provide written informed consent 
 
 
 
Table 2:  Characteristics at Baseline for Women in the WM Study.49  Characteristics 
are included on a total of 165 women. 
Characteristic N (%) or Mean (SD) 
Age (years) 25.1 (5.6) 
Married 118 (74.2) 
Education level completed  
     Primary 65 (40.6) 
     Secondary school 83 (51.9) 
First pregnancy 44 (29.0) 
Multiparous women, previous pregnancies 2.5 (1.8) 
Someone else knew HIV status at enrollment 62 (38.8) 
Disclosed HIV status to husband/partner at enrollment 41 (26.1) 
Completed pre-intervention period 132 (80.0) 
Adherence, pre-intervention period (%) 76.0 (24.9) 
 
 
 
 
   
16 
 
WM Intervention48 
All pregnant women in the WM study used WPCs, equipped with real-time EDM 
capacity, to hold their ART medication.  Subjects underwent in-depth debriefing on how 
to use the WPCs.  Following enrollment into the study, women underwent a one month 
run-in period to ensure that they would be able to use the WPC without technical or 
social barriers to its use.  After successful completion of the one month pre-intervention 
period, women were randomized into either the control or intervention study arm (Figure 
5).  Over the course of the 6-month intervention, until 3 months post-partum, subjects in 
the intervention arm received two-step adherence feedback.  This entailed a text message 
reminder if a subject failed to open her WPC within 60 minutes of dose time and monthly 
counseling using her most recent WPC adherence data.  A counselor reviewed the 
adherence data with the patient and provided feedback based on a 95% adherence 
threshold.  If adherence was ≥ 95% in the previous month, the counselor provided 
positive feedback.  If adherence was < 95% in the previous month, the counselor 
discussed reasons for lapses and ways to improve adherence.  Subjects in the control arm 
used WPCs, but did not receive the two-step adherence feedback intervention.  
Researchers and all subjects were aware of which treatment was being administered.  The 
standard of care (Option B+) was followed for all HIV+ pregnant women and all HIV-
exposed infants.  
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Figure 5.  Selection of WM Participants.  Enrollment took place from June 2015 to 
January 2016.  The pre-intervention period of 1 month took place from June 2015 to 
February 2016.  Following Month 1 of pre-invention, the intervention period began at 
Month 2 and continued through 3 months post-partum.  The intervention period took 
place from July 2015 to October 2016. 
 
 
At Baseline:
165 HIV+ pregnant 
women initiating 
ART enrolled
withdrawals
At 1 Month:
133 subjects 
randomized
*Entebbe Site: 66 
women
31 women to
Control Arm
10 lost to follow-up;
1 withdrew
20 women 
completed study
35 women to 
Intervention Arm
8 lost to follow-up
27 women 
completed study
*Mityana Site: 67 
women
33 women to 
Control Arm
2 lost to follow-up
31 women 
completed study
34 women to 
Intervention Arm
2 died;
2 lost to follow-up;
1 withdrew
29 women 
completed study
By subject: 1 
-  1 moved 
By study team: 31 
-  16 missed visit at Month 1 
-  6 had poor signal for proper WPC use 
-  4 miscarried before visit at Month 1 
-  3 refused to use WPC/take medication 
-  1 found to be HIV-negative 
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WIN Ambidirectional Cohort Sub-Study  
Eligible WM women were approached for informed consent and enrollment into 
the WIN study (Table 3; Figure 6).  If a woman had a fetal miscarriage or fetal death 
before delivery, she was not approached for consent.  Delivery data, provision of infant 
NVP prophylaxis, and timing to EID testing (involving a HIV DNA test using a dried 
blood specimen from a heel stick) were abstracted from available medical registers for 
each infant.  Directed questioning was used to survey mothers of WIN mother-baby 
dyads regarding beliefs and knowledge about how HIV can be transmitted to infants and 
the best feeding method for HIV-exposed infants.  Women were asked:  1) Can you 
transmit HIV to your baby; 2) How can you transmit HIV to your baby; 3) Does taking 
ART reduce the risk of transmitting HIV to your baby; 4) Does infant ARV prophylaxis 
reduce their risk of getting HIV; and 5) What is the best way to feed your baby? 
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Table 3:  Inclusion and Exclusion Criteria for WIN Study 
Inclusion Criteria • Only women enrolled in the WM study who completed 
at least 1 month of study participation 
o Only infants born to eligible women who provide 
written informed consent for their infant’s 
participation 
▪ Even if infant died after delivery 
Exclusion Criteria • Infants not born to HIV+ mothers 
• Infants of HIV+ mothers who do not consent for their 
infant’s participation 
• Mothers who are not proficient or fluent in either English 
or Luganda (one of the major languages spoken in 
Southern Uganda)47 
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Figure 6.  Selection of WIN Participants.  Following enrollment into the WM study at 
either Entebbe or Mityana, women were randomized to either control or intervention arm.  
WIN enrollment started in January 2016 and continued through July 2016.  Site and 
intervention status of each infant was based on which site the infant’s mother reported to 
for the study and which study arm the mother was assigned to, respectively. 
165 women 
enrolled in WM 
study
121 mother-baby 
dyads eligible for 
WIN study
97 mother-baby 
dyads enrolled in 
WIN study
*Entebbe Site: 46 
women
randomized
22 to
Control Arm
2 infants lost to 
follow-up
20 infants
completed EID test
24 to 
Intervention Arm
1 infant died at 1 
month of age
23 infants
completed EID test
*Mityana Site: 51 
women
randomized
24 to 
Control Arm
2 infants lost to 
follow-up; 1 
infant reportedly 
stolen
21 infants
completed EID test
1 infant died
27 to 
Intervention Arm
6 infants lost to 
follow-up
21 infants
completed EID test
Ineligible WM subjects:  44 
-  32 WM subjects not randomized (see 
   Figure 5) 
-  8 fetal demises/stillbirths after 
   randomization 
-  4 WM women lost to follow-up 
   before WIN enrollment 
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As per standard of care under Option B+ policy, all infants delivered at a study 
health facility were intended to receive NVP at birth and to be discharged to home with a 
6-week supply of NVP prophylaxis.  If delivery did not occur at a study health facility or 
a health facility with NVP supply, mothers were instructed to report to a study or other 
health facility to receive the 6-week supply of NVP prophylaxis.  All mothers were 
expected to present 6 weeks after delivery for EID testing of their baby.  
 
Statistical Analysis 
 Descriptive statistics and differences in: 1) time to EID testing, and 2) infant NVP 
administration were generated and analyzed using two-sample tests of means and 
Pearson’s chi-squared tests with SAS Version 9.4.  Infants were further categorized into 
one of three groups for analysis of time to EID testing, depending on how many days 
elapsed from date of delivery to date of EID testing:  1) 42 days, 2) 43 – 49 days, or 3) > 
49 days. 
 
RESULTS 
 
Quantitative 
 Of the 165 WM study subjects, 121 were eligible for the WIN study (i.e. 
completed at least one month of WM study procedures and had not had a fetal death or 
stillbirth prior to consent).  The enrollment rate for the WIN study was 80% (n = 97).  
Although there was lag time from initial WM recruitment (June 2015) to WIN enrollment 
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(January 2016) and continued LTFU of WM women, there was no significant difference 
in mean length of days between WM and WIN enrollment time with respect to WM 
randomization status (control = 198.8 days, intervention = 196.5 days, p = 0.86).  When 
stratified by study site there was no significant difference either.  At Entebbe, mean 
length of days between WM and WIN enrollment time with respect to WM 
randomization status was 185.3 days for the control group and 191.7 days for the 
intervention group (p = 0.66).  At Mityana, the mean length of days was 210.5 for control 
subjects and 200.7 for intervention subjects, respectively (p = 0.63).   
  While births were expected to be at either Entebbe or Mityana study health 
facilities, some women gave birth at different health facilities where ANC and ART 
treatment was not received, or at home where similar services were not received (Figure 
7).  There were no differences in location of delivery between control and intervention 
infants, though infants delivered at non-study health facilities were less likely to receive 
any NVP prophylaxis overall (Table 4).   
With respect to the outcome of NVP prophylaxis, there were no differences in 
receipt of NVP prophylaxis for the first 6 weeks of life between study arms:  86.7% of 
control infants received NVP and 82% of intervention infants received NVP (p = 0.53) 
(Figure 8). When stratified by study site, 86.4% of control infants and 75% of 
intervention infants received NVP at Entebbe (p = 0.46), and 87.0% of control infants 
and 88.5% of intervention infants received NVP at Mityana (p = 1.00).  Though there 
were no significant differences in receipt of 6-week NVP supply with respect to WM 
randomization status by study site, a slightly higher proportion of both the control and 
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intervention infants received NVP at Mityana compared to Entebbe (Table 4).  All 
women at Mityana gave birth at a study heath facility, compared to 75.6% of women at 
Entebbe who gave birth at a study health facility (Figure 7).   
 
 
Figure 7.  Place of Infant Delivery.  All women at Mityana delivered at a study health 
facility, compared to 75.6% of women at Entebbe delivered at a study health facility. 
*Although 46 women were enrolled into the WIN study at Entebbe, 1 infant who was in the 
intervention group had an unknown “place of delivery” status despite there being information 
collected on NVP prophylaxis and EID testing outcome measures.  At Mityana, though 51 
women were enrolled into the WIN study, 1 woman who was in the control group was lost to 
follow-up before delivering her infant.  
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Figure 8.  Receipt of NVP Prophylaxis.  NVP was to be administered intrapartum and 
women were to receive a 6-week supply of NVP prophylaxis for their baby at discharge.  
Note:  Percentages indicate the proportion of control or intervention infants who received NVP 
prophylaxis among all control (n=45) or intervention (n=50) infants in the study. 
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Table 4:  Infant Delivery Location by WM Randomization Status.  Mother’s 1) place 
of delivery, 2) receipt of intrapartum NVP, and 3) receipt of 6-week supply of NVP for 
infant were compared by intervention status by one sample tests of proportion and 
Pearson’s χ2 tests.  The sample sizes for control and intervention infants were 45 and 50, 
respectively.   
Characteristic Location+ Control 
Infants  
(n = 45) 
Intervention 
Infants  
(n = 50)  
P-value  
Place of Delivery  Study Health 
Facility   
39 (86.7%)*  45 (90.0%)**  0.51 
 Different Health 
Facility   
6 (13.3%) 5 (10.0%) 0.76 
Receipt of intrapartum 
NVP  
Study Health 
Facility 
31 (79.5%)# 35 (77.8%)## 0.99 
 Different Health 
Facility 
4 (66.7%) 3 (60.0%) 1.00 
Receipt of 6-week 
supply of NVP for 
infant 
Study Health 
Facility 
34 (87.2%)‡ 37 (82.2%)‡‡ 0.69 
 Different Health 
Facility 
5 (83.3%) 3 (60.0%) 0.55 
Note:  All deliveries at non-study health facilities were among women at Entebbe. 
+Study health facility refers to either Entebbe or Mityana. 
*39 (86.7%) of the 45 control infants were delivered at a study health facility. 
**45 (90.0%) of the 50 intervention infants were delivered at a study health facility. 
#31 (79.5%) of the 39 control infants that were delivered at a study health facility received 
intrapartum NVP.  
##35 (77.8%) of the 45 intervention infants that were delivered at a study health facility received 
intrapartum NVP.  
‡34 (87.2%) of the 39 controls infants that were delivered at a study health facility received a 6-
week supply of NVP at discharge. 
‡‡37 (82.2%) of the 45 intervention infants that were delivered at a study health facility received a 
6-week supply of NVP at discharge. 
 
  
With respect to the outcome of EID testing, there was no difference in mean days 
to EID testing (control = 51.9 days, intervention = 51.3 days, p = 0.86).  When stratified 
by study site, there remained no difference between intervention and control infants.  At 
Entebbe, mean days to EID testing was 51.8 days for the control group and 50.4 days for 
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the intervention group (p = 0.67).  At Mityana, the mean days to testing was 52.0 days 
and 52.1 days, respectively (p = 0.99).  Although not significant, infants took longer on 
average to present for EID testing at Mityana than they did at Entebbe.  When analyses of 
time to EID test were conducted based on three different categories of day ranges (i.e. 42 
days, 43 – 49 days, and > 49 days), there was no statistical difference in time from 
delivery to EID testing with respect to WM randomization status (p = 0.75) (Figure 9).  
Furthermore, when stratified by study site, proportions of infants in the three different 
categories did not differ statistically with respect to WM randomization status (at Entebbe 
p = 0.29, at Mityana p = 0.70).  Stratification by study site for these three categories 
should be interpreted cautiously due to expected counts of less than 5 in > 20% of the 
cells in the contingency table. 
 Only one infant tested positive for HIV.  This infant was born to a woman who 
had been assigned to the control group.  Forty-four days elapsed from delivery to EID 
testing, which is supposed to occur at 6 weeks (42 days) of life.  This infant later died at 
47 days of life, secondary to dehydration and diarrhea by verbal autopsy report.  A 
second infant, born to a woman in the intervention group, died at 30 days of life, which 
was prior to any anticipated EID testing.  Verbal autopsy indicated cause of death to be 
infection.  The mother of a third infant, assigned to the intervention group, died during 
labor.  This infant still received EID testing, though at 46 days of life (4 days past the 
instructed date).   
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Figure 9.  Time to Initial HIV Test for Infants.  Women were instructed to bring their 
infants to a study health facility for EID testing at 6 weeks (42 days) of life.  For the 
purpose of analysis, infants were categorized into one of three groups based on time to 
HIV testing following delivery.  These groups included:  1) at 42 days, 2) between 43 and 
49 days, and 3) greater than 49 days.  
Note:  Percentages indicate the proportion of control or intervention infants who received HIV 
testing during the designated period among all control or intervention infants who received HIV 
testing in the study. 
 
Qualitative 
Of the 97 mother-baby dyads enrolled in the WIN study, a total of 14 women 
declined to answer the questionnaire regarding their knowledge about the possible ways 
that HIV could be transmitted to their infants.  Directed questioning about modes of HIV 
transmission to infants revealed common themes such as:  maternal ART nonadherence, 
transmission through breastfeeding, and unsafe delivery (Table 5).  All mothers 
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prevent transmission of HIV to infants.  Despite reporting unsafe delivery as a risk factor 
for HIV transmission to infants, 11.6% (11/95) of women delivered at a health facility 
different from where they received ART care.  It is worth repeating that there was 
variation in delivery location by study site (Figure 7).  Regardless of place of delivery, 
only 85.3% (81/95) of infants received some form of NVP prophylaxis, and only 14.1% 
(12/85) of infants received their EID test at the recommended 6 weeks of life. 
Regarding the question of best feeding method for their HIV-exposed infants, a 
total of 12 women of the 97 mother-baby dyads enrolled in the WIN study declined to 
answer.  Of the 85 women who completed the questionnaire, 95.3 % (n = 81) of women 
identified breastfeeding as the best feeding method, yet only 24.7% (n = 21) knew about 
the WHO EBF recommendations, and mixed feeding practices were endorsed by 4.7% (n 
= 4) of mothers (Table 6).   
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Table 5:  Maternal Knowledge of HIV Transmission to Infants.  At baseline, all WIN 
women were asked to complete a questionnaire regarding their knowledge of HIV 
transmission to infants.  Of the 97 enrolled women, 14 declined to answer the 
questionnaire.  A total of 83 mothers provided answers.  Women were not limited in the 
number of responses they could give for the potential “method of transmission”.  Of the 
83 women who completed the questionnaire, 34 gave multiple responses. 
Method of Transmission Number of 
responses 
(%)* 
Number of women who 
gave another response 
(%)** 
Maternal ART nonadherence 39 (47.0 %) 17 (43. 6 %) 
Breastfeeding 30 (36.1 %) 20 (66.7 %) 
During delivery 22 (26.5 %) 12 (54.5 %) 
Unsafe sex with partner 8 (9.6 %) 7 (87.5 %) 
Sharing sharps 6 (7.2 %) 3 (50.0 %) 
Contact with blood 6 (7.2 %) 4 (66.7 %) 
Infant ART prophylaxis nonadherence 4 (4.8 %) 3 (75 %) 
Other# 4 (4.8 %) 4 (100 %) 
Mixed feeding 2 (2.4 %) 1 (50 %) 
*In total, the 83 women gave 135 responses.  % represents the proportion of women who gave the 
respective response out of the total 83 women who answered the questionnaire. 
**The n reported represents the number of women who gave the respective method as a response, 
in addition to another method.  % represents the proportion of these women out of all the women 
who gave the respective method as a response (e.g. 43.6% of the 39 women who gave “maternal 
ART nonadherence” as a method of HIV transmission also gave another method of transmission).  
#Responses in the other category included: not eating well, through body cuts, living in denial, 
and not attending care. 
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Table 6:  Reported Feeding Behaviors of HIV+ Mothers.  At baseline, all WIN 
women were asked to complete a questionnaire regarding their knowledge of the best 
feeding method for their HIV-exposed infant.  Of the 97 enrolled women, 12 declined to 
answer the questionnaire.  A total of 85 mothers provided answers.  Each woman’s 
response was recorded under one category.  Of the 85 women who completed the 
questionnaire, 81 (95.3%) identified breastfeeding as the best method, but only 21 
(24.7%) knew about the WHO EBF recommendations.  
Method of Feeding Number of Responses (%) 
Breastfeeding (any) 60 (61.9 %) 
Exclusive breastfeeding for at least 6 months 21 (21.6 %) 
Mixed feeding* 4 (4.1 %) 
No response 12 (12.4 %) 
*Cow’s milk or porridge were as an adjunct with breastfeeding. 
 
DISCUSSION  
 
This study is the first to the investigators’ knowledge to report on infant 
adherence to PMTCT in the setting of maternal ART adherence interventions.  This is 
one of the few studies to follow a cohort of infants through the PMTCT-cascade under 
Option B+ conditions. While this study did not demonstrate a difference in infant primary 
outcomes of NVP receipt and time to EID testing with respect to a maternal adherence 
intervention, it does highlight some trends of special concern in the infant cascade of 
PMTCT.  
 With respect to the primary outcome of NVP receipt, there was no significant 
difference between intervention and control mother-infant pairs.  There was no 
significant difference in the proportion of women who did not receive either intrapartum 
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NVP or a 6-week supply of NVP prophylaxis for their respective infants among the 
women who delivered at study health facilities.  Among the women in the control group 
who delivered at a study health facility, only 79.5% received intrapartum NVP, and only 
87.2% received a 6-week supply of NVP prophylaxis for their respective infants.  
Similarly, among the women in the intervention group who delivered at a study health 
facility, only 77.8% received intrapartum NVP, and only 82.2% received a 6-week supply 
of NVP prophylaxis for their respective infants.  Among the women in the control group 
who delivered at a non-study health facility, only 66.7% received intrapartum NVP, and 
only 83.3% received a 6-week supply of NVP prophylaxis for their respective infants.  
Among the women in the intervention group who delivered at a non-study health facility, 
only 60.0% received intrapartum NVP and 60.0% received a 6-week supply of NVP 
prophylaxis for their respective infants.  The slightly higher frequency of receipt of a 6-
week supply of NVP for infants at Mityana compared to Entebbe may be attributed to the 
increased use of study health facility for deliveries among the women at Mityana.  
Similarly, the increased delivery of intrapartum NVP among Mityana deliveries could be 
due to exclusive deliveries at a study health facility.  Per Option B+ policy, women 
should receive NVP both intrapartum and for 6-weeks postnatally for their infants at 
these health facilities.   
The Global Plan report does not give information on the proportion of HIV-
exposed infants receiving NVP prophylaxis in Uganda.  It does however report that only 
63% of Ugandan children living with HIV accessed ART treatment in 2015.19  The 
Global Plan report also reveals that in 2015 in Uganda, only 33% of infants born to HIV+ 
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women received HIV testing within two months of life.19  This is lower than the 
aggregate 51% of infants who received HIV testing in all 21 priority countries of the 
Global Plan.19  In the WIN study reported here, 85.5% of infants (71/85), regardless of 
their randomization status, received EID testing within 2 months.  In the control group 
and in the intervention group, 87.8% (36/41) and 79.6% (35/44) of infants received their 
EID testing within 2 months, respectively (p = 0.31).  
The results of this study did not demonstrate that the 2-step feedback intervention 
significantly changed the mean time to EID testing of HIV-exposed infants.  However, 
for the majority of infants (85.9 %), the time to HIV testing for both control and 
intervention arms was greater than the recommended 42 days, with a median of 48 days.  
Infants testing negative at EID will ideally undergo additional tests at 6 months of age, 1 
year of age, and once breastfeeding stops.50  This is to confirm that infants remain 
uninfected, and if they become HIV-infected, that they begin ART treatment as soon as 
possible.50  One infant, born to a mother in the control group, tested positive for HIV at 
44 days of life, and later died at 47 days of life. 
Though the WHO does not currently recommend HIV DNA testing at birth for all 
exposed infants, as is done in the United States and other high-resource settings, results 
from the WIN study reported here indicate instances where infants could have potentially 
benefited from earlier HIV testing.50,51  The mortality outcomes which occurred in this 
study offer support for the addition of HIV DNA testing at birth to PMTCT programs.  
One infant, born to a mother in the control group, tested positive for HIV at 44 days of 
life, and later died at 47 days of life.  Another infant, born to a mother in the intervention 
   
33 
 
group, died prior to EID testing at 30 days of life.  Had the death of the infant who died 
after testing positive for HIV been attributable to HIV infection, mortality could have 
potentially been prevented had HIV testing been completed at birth, and ART treatment 
initiated immediately after a HIV+ result.  Although the HIV status of the infant who died 
at 30 days of life was unknown, HIV testing at birth could have similarly allowed for 
immediate ART treatment had the infant been infected, and prevented an HIV-related 
death.  Better health outcomes among infants are a priority and preventing infant death 
supports incorporating infant HIV testing at birth.  Eleven other infants in total were lost 
to follow-up before EID testing, 5 control infants and 6 intervention infants.  Similarly, 
retention of infants in the pediatric components of the PMTCT-cascade could potentially 
improve with the addition of HIV testing at birth, as well as improve the Global Plan 
targets of initiating 90% of all HIV-infected children on ART.19  However, given that 
LTFU involving activities in the PMTCT-cascade has been a barrier to preventing HIV 
transmission from mothers to their children, recently available point-of-care technology 
which offers same day results of HIV testing may be an appropriate strategy to improve 
uptake of HIV infant testing at 6 weeks follow-up or any time point.50 
There are a number of limitations to this study, the first being that sample size 
was secondary to attrition in the WM study, thus limiting the power of the WIN study.  
With an assumption that 5% of eligible women would refuse to participate, 123 women 
were estimated to be needed for 80% power to detect a 25% difference in infant 
outcomes between intervention and control groups.  However, only 121 WM women 
were eligible for the WIN study and only 97 enrolled, with a refusal rate of 20% (in some 
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cases, due to further attrition from the WM study as some women could not be located to 
consent and enroll into the WIN study).  Subsequently, 11 infants were lost to follow-up 
and 1 infant died prior to EID testing, with another infant dying shortly after testing at 47 
days of life. 
It is important to address that even in the setting of a randomized trial for 
adherence, the retention rate of women was very poor.  Furthermore, there was 
differential retention between the study site in urban Entebbe, and the study site in rural 
Mityana, which is likely multifactorial.  For improved retention rates in future 
interventions, investigators would benefit from knowing the reasons for retention 
challenges.  For example, women could have chosen to attend health facilities that were 
further from their homes in order to avoid stigma in their communities, and consequently 
delayed reporting to health facilities due to the inconvenience of a further commute. 
Another limitation of this study is the completeness of routinely collected health 
facility data.  This suggests that better surveillance is needed to accurately capture study 
and health facility activity.  For example, one infant was delivered at a study health 
facility, yet there was no documentation regarding receipt of NVP prophylaxis.  In 
another situation, the medical registry had information regarding receipt of NVP 
prophylaxis and time to EID testing for an infant, but did not have the infant’s place of 
delivery.  Lapses in documentation were nondifferential between the intervention and 
control groups.  With proper care, these unknowns can be avoided.  It is important to 
follow up on missing data. 
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Preliminary findings from the WM study revealed that, among the 165 women, 
there were 179 WPC lapses, with a mean lapse of 1.1 per woman over approximately 
4,837 days.49  Causes for lapses included behavioral (n = 72, 40%), technical (n = 58, 
32%), as well as unknown reasons (n = 49, 27%).49  The top behavioral reasons were 1) 
fear of side effects (29.2%); 2) inconvenience (19.4%); and 3) fear of disclosure 
(18.1%).49  The main technical reason was signal strength (70.7%).49  Similarly, 
inconvenience and fear of disclosure could prevent a mother from taking her infant to 
EID testing at 6 weeks of life.  If a woman was not adhering to maternal components of 
PMTCT, it is reasonable that for similar reasons, she may be less likely to be able to 
adhere to the pediatric components of PMTCT. 
Importantly, the WIN results are interpreted as intention-to-treat with respect to 
the WM study.  For the purposes of this paper it is unknown whether women were 
actually adhering to their own ART treatment.  As mentioned above it is reasonable to 
believe a woman’s own adherence will affect the adherence of her infant.  Mothers had a 
mean of 76% adherence in the pre-intervention period of the WM study.49  This is lower 
than the 95% adherence threshold which is considered optimal, where if maintained, 
allows for effective long-term viral suppression.4,5  Though adherence was lower than 
95% at baseline, the purpose of the WM study was to improve adherence.  Future 
analyses regarding ART adherence among women in the WM study, may provide insight 
into mothers’ impacts on infant adherence. 
All infants, non-HIV-exposed and HIV-exposed alike, benefit from exclusive 
breastfeeding for the first 6 months of life.52  EBF reduces morbidity and mortality in all 
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infants, and has the additional advantage of reducing vertical transmission of HIV.52  
Though introducing other appropriate solid foods is necessary to provide the energy 
intake needed by infants beyond 6 months of age, introducing mixed feeding methods too 
early increases infants’ susceptibility to gastrointestinal infections.52  Supporting the 
benefits of breastfeeding, a study examining MTCT-related outcomes from a randomized, 
double-blind, placebo-controlled trial in Tanzania reported that the risk of vertical HIV 
transmission was significantly reduced by EBF through 12 months of age.53  
Additionally, a randomized study examining HIV infection and death by 24 months of 
life in HIV-exposed infants, conducted in Zambia, demonstrated that among infants who 
were HIV+ by 4 months of age, death was significantly more common among those who 
were weaned from breastfeeding at 4 months of life compared to those who were 
breastfed for as long as their mothers chose to do so.54  This latter group of mothers 
breastfed for a median of 16 months.54  Furthermore, the study found that weaning infants 
from breastfeeding at 4 months of age did not improve HIV-free survival among HIV-
exposed infants.54 This study concluded that immunological and nutritional benefits of 
extended breastfeeding outweigh the risk of HIV transmission through breastfeeding.54  
Multiple studies showing uniform results have led to the conclusion that breastfeeding is 
the best feeding method for all infants.52  
While few women (24.7 %) knew about the WHO EBF recommendations and 
some women (4.7%) endorsed mixed feeding methods at baseline, in the WIN study 
reported here, study sites addressed these gaps in maternal knowledge.  However, it is 
important to consider the impact of the HIV-stigma related to EBF.  The cultural norm in 
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many resource-limited settings, including Uganda, is for mothers to feed their infants 
through breastfeeding in conjunction with other liquids and foods before 6 months of 
age.52,55  Focus group discussions in Kenya among HIV+ and HIV-negative pregnant and 
postpartum women and their male partners revealed that EBF is considered a feeding 
practice reserved only for HIV+ women.56  Thus, fear of discrimination is a serious 
barrier to EBF for many women regardless of HIV status.56  Due to the potential for 
stigma in their communities or at home, it is possible that the women in this study did not 
exclusively breastfeed their infant for the first 6 months of life, even if they reported this 
as the best method to feed their infants.  To maximize PMTCT benefits, health facilities 
should offer information regarding best feeding practices in ways that minimize stigma, 
such as in settings inclusive of both HIV+ and HIV-negative women.37 Investigators will 
benefit from comparing mothers’ baseline responses to the feeding questionnaire with 
mothers’ adherence to their own ART treatment in the WM study. 
Furthermore, knowing why a woman did not give birth at a study site could give 
insight into the HIV-stigma related to attending health facilities with combined ANC and 
ART services.57  Knowledge regarding these perceptions could better inform PMTCT 
interventions.  And although it was not possible to discern at the time, Option B+ 
stakeholders and investigators of future interventions would benefit from knowledge 
regarding why NVP prophylaxis was not received by women who delivered at a study 
health facility.   
Despite the limitations of the WIN study, its nested-study design is a significant 
strength.  The results of the WIN cohort of infants can be generalized to the other infants 
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born in the WM study and provide insight as to how other interventions, similar to the 
one used in the WM study, may impact the infants born to HIV+ women in low-resource 
settings.    
 
CONCLUSION  
 
   Despite the lack of statistical significance in this study’s outcome measures, 
better overall adherence to PMTCT is needed.  Infants in both the control and 
intervention arms of the study had a mean time to EID testing that was greater than the 
recommended 42 days.  Mothers are not the only ones who impact adherence to pediatric 
components of PMTCT, as evidenced by the infant who still received EID testing, despite 
her mother’s death during labor.  Infants depend on their mothers’ and caregivers’ 
adherence to feeding modalities, administration of NVP prophylaxis, and taking them to 
EID testing.  Investigators need to consider both mother and caregiver barriers to 
retention in care, as well as adherence to the pediatric components of PMTCT.  Although 
Uganda has reduced new HIV infections among children by 86% since 2009, more 
information regarding infant adherence is needed in order to eliminate new HIV 
infections among children.19  Uganda met the 2015 Global Plan goal of ensuring ART 
access to 90% or more of HIV+ pregnant women, but there is no evidence that similar 
success has been achieved in ensuring infants receive NVP prophylaxis.19  More research 
is needed to improve understanding of feasible and effective methods to promote infant 
adherence of activities in the PMTCT-cascade, including NVP prophylaxis.   
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